Escitalopram Best at Stopping Depression Relapse
Escitalopram Best at Stopping Depression Relapse
Escitalopram Best at Stopping Depression Relapse
Key points
اہم نکات
मुख्य बातें
- Escitalopram is the best antidepressant at keeping depression away long-term, a major analysis of 115 trials involving more than 30,000 people found.
- Published in The Lancet Psychiatry, the study found escitalopram, followed by agomelatine and duloxetine, beat fluoxetine (Prozac) at keeping patients well, and people on escitalopram or duloxetine were also less likely to stop their medication.
- Experts stressed the differences were modest, the results are group averages that cannot predict the best drug for any one person, and nobody doing well on their current medicine should switch.
- Escitalopram is the best antidepressant at keeping depression away long-term, a major analysis of 115 trials involving more than 30,000 people found.
- Published in The Lancet Psychiatry, the study found escitalopram, followed by agomelatine and duloxetine, beat fluoxetine (Prozac) at keeping patients well, and people on escitalopram or duloxetine were also less likely to stop their medication.
- Experts stressed the differences were modest, the results are group averages that cannot predict the best drug for any one person, and nobody doing well on their current medicine should switch.
- Escitalopram is the best antidepressant at keeping depression away long-term, a major analysis of 115 trials involving more than 30,000 people found.
- Published in The Lancet Psychiatry, the study found escitalopram, followed by agomelatine and duloxetine, beat fluoxetine (Prozac) at keeping patients well, and people on escitalopram or duloxetine were also less likely to stop their medication.
- Experts stressed the differences were modest, the results are group averages that cannot predict the best drug for any one person, and nobody doing well on their current medicine should switch.
Escitalopram is the best antidepressant at keeping depression away long-term, a major analysis of 115 trials involving more than 30,000 people found. Published in The Lancet Psychiatry, the study found escitalopram, followed by agomelatine and duloxetine, beat fluoxetine (Prozac) at keeping patients well, and people on escitalopram or duloxetine were also less likely to stop their medication. Experts stressed the differences were modest, the results are group averages that cannot predict the best drug for any one person, and nobody doing well on their current medicine should switch. Doctors already advise staying on antidepressants for at least six months after recovery, then tapering off gradually to prevent relapse.
Escitalopram is the best antidepressant at keeping depression away long-term, a major analysis of 115 trials involving more than 30,000 people found. Published in The Lancet Psychiatry, the study found escitalopram, followed by agomelatine and duloxetine, beat fluoxetine (Prozac) at keeping patients well, and people on escitalopram or duloxetine were also less likely to stop their medication. Experts stressed the differences were modest, the results are group averages that cannot predict the best drug for any one person, and nobody doing well on their current medicine should switch. Doctors already advise staying on antidepressants for at least six months after recovery, then tapering off gradually to prevent relapse.
Escitalopram is the best antidepressant at keeping depression away long-term, a major analysis of 115 trials involving more than 30,000 people found. Published in The Lancet Psychiatry, the study found escitalopram, followed by agomelatine and duloxetine, beat fluoxetine (Prozac) at keeping patients well, and people on escitalopram or duloxetine were also less likely to stop their medication. Experts stressed the differences were modest, the results are group averages that cannot predict the best drug for any one person, and nobody doing well on their current medicine should switch. Doctors already advise staying on antidepressants for at least six months after recovery, then tapering off gradually to prevent relapse.
Most read
سب سے زیادہ پڑھی گئی
सबसे ज़्यादा पढ़ी गई
- Loading...
Get news in your inbox
خبریں اپنے ان باکس میں حاصل کریں
खबरें अपने इनबॉक्स में पाएं
One email when new stories are published. No spam, unsubscribe anytime.
نئی خبریں شائع ہونے پر ایک ای میل۔ کوئی سپیم نہیں، کسی بھی وقت ان سبسکرائب کریں۔
नई खबरें प्रकाशित होने पर एक ईमेल। कोई स्पैम नहीं, कभी भी अनसब्सक्राइब करें।